Vivus sues Actavis over Qsymia patent challenge; Sri Lanka eyes generics-first prescribing policy;

@FiercePharma: Roche neighbors sue, claiming contamination lowered home prices. More | Follow @FiercePharma

@EricPFierce: ICYMI: MS Pharma in Jordan gets $30M development loan to expand its drug manufacturing. Story | Follow @EricPFierce

@CarlyHFierce: German court deals another EU patent blow to Lilly's blockbuster Alimta. Article | Follow @CarlyHFierce

> U.S.-based Vivus ($VVUS) sued Actavis ($ACT) for infringement after the generics maker challenged two patents on Vivus' obesity drug Qsymia, which combines two older drugs, phentermine and topiramate. Filing

> Sri Lanka's government is set to launch a new drug policy requiring doctors to prescribe generics if a copycat drug is available. Report

> The U.S. Supreme Court sent a University of Notre Dame contraception case back to a lower court to be reviewed in light of a related high court ruling in the Hobby Lobby case. Report

> Reig Jofre and Kern Pharma inked a deal with Maruishi Pharma to market an injectable anesthetic for hospital use in Japan. Report

> Novo Nordisk ($NVO) released data suggesting that its new obesity drug Saxenda could help fight weight-related health problems as patients lose weight. Report

Medical Device News

@FierceMedDev: ICYMI Friday: J&J ordered to hand over $5.6M in vaginal mesh trial. Report | Follow @FierceMedDev

@VarunSaxena2: Four clinical trial patients die in test of Sunshine Heart ventricle assist device. Story | Follow @VarunSaxena2

@EmilyWFierce: Get this week's edition of FierceLifeSci here! | Follow @EmilyWFierce

> Patient advocates call for increased transparency as superbug tied to endoscopes continues. News

> FDA approves novel blood purifier that treats rare condition in hemodialysis patients. Story

> Icon launches new medical device research division. Article

Biotech News

@FierceBiotech: Baxter and its controversial partner CTI claim a win in PhIII blood cancer study. Report | Follow @FierceBiotech

@JohnCFierce: From the weekend file: UPDATED: Merck to shutter Cubist unit in May, axing most of the 128 R&D staffers. Report | Follow @JohnCFierce

@DamianFierce: Hey @FierceBiotech's podcast is now available on Stitcher. If you know what that means, here you go. | Follow @DamianFierce

> Biopharma's new normal: Constant makeovers leave R&D jobs at permanent risk. Story

> Baxter and its controversial partner CTI claim a win in PhIII blood cancer study. News

> AcelRx hammered (again) after FDA demands a new Zalviso study after all. Article

Biotech IT News

> NIH puts data stitching at top of precision medicine to-do list. More

> Broadly positive reactions roll in for FDA's drug shortages app. Report

> Ubisoft creates therapeutic video game to treat lazy eye. Item

> Intel-GE joint venture teams with Xavier U. to test health tech. Story

> AstraZeneca's rapid-fire IT dealmaking continues with Elixir hookup. Article

CRO News

> Altasciences partners up for early-stage R&D. Article

> Contractor Almac gets into the clinic with a candidate of its own. More

> Icon doubles down on med tech with latest offering. Story

> Patheon snags another CMO amid its global expansion. News

> WuXi eyes major growth in 2015 with plans to spend big. Article

Animal Health News

> Heska scores record 2014 sales on 'more focused' strategy. More

> EMA seeks input on new guidelines to combat antibiotics resistance. Item

> Researchers tap dogs for insights into stopping cancer metastasis. Article

> Future veterinarians go to Congress to discuss student loan debt. Story

> McDonald's ditches antibiotics-raised chicken as legislators launch bill to curb use. Report

And Finally... A new National Health Service heart-age calculator is stirring up some protest. Report

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.